Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Tasquinimod,Ixazomib Citrate,Lenalidomide
Therapeutic Area : Oncology
Study Phase : Phase I
Recipient : Wistar Institute of Anatomy and Biology
Deal Size : Undisclosed
Deal Type : Acquisition
Active Biotech Acquires Exclusive Rights to Patents of Tasquinimod in Combination Therapy
Details : Under the terms of the agreement, Wistar grants Active Biotech a global exclusive license to develop and commercialize tasquinimod in combination therapy, as a treatment for multiple myeloma.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
May 22, 2024
Lead Product(s) : Tasquinimod,Ixazomib Citrate,Lenalidomide
Therapeutic Area : Oncology
Highest Development Status : Phase I
Recipient : Wistar Institute of Anatomy and Biology
Deal Size : Undisclosed
Deal Type : Acquisition
Lead Product(s) : Tasquinimod
Therapeutic Area : Oncology
Study Phase : Phase II
Recipient : MD Anderson Cancer Center
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Tasquinimod is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Primary Myelofibrosis.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
March 25, 2024
Lead Product(s) : Tasquinimod
Therapeutic Area : Oncology
Highest Development Status : Phase II
Recipient : MD Anderson Cancer Center
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Laquinimod
Therapeutic Area : Ophthalmology
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Active Biotech Strengthens the Patent Protection for Laquinimod in Eye Disorders
Details : Laquinimod is a first-in-class immunomodulator that induces immune tolerance and reduces the pro-inflammatory and angiogenic response by targeting of the myeloid cell compartment.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
April 26, 2022
Lead Product(s) : Laquinimod
Therapeutic Area : Ophthalmology
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tasquinimod
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Oncode Institute
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : Under the terms of the agreement, Oncode Institute, a foundation under the laws of the Netherlands, acting on behalf of Erasmus Universiteit Medisch Centrum, grants a global exclusive license to develop and commercialize tasquinimod worldwide in MF to Ac...
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
February 09, 2022
Lead Product(s) : Tasquinimod
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Oncode Institute
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Laquinimod
Therapeutic Area : Ophthalmology
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study of Laquinimod Eye-drops in Healthy Participants
Details : Laquinimod is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Eye Diseases.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
January 11, 2022
Lead Product(s) : Laquinimod
Therapeutic Area : Ophthalmology
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tasquinimod
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Preclinical Tasquinimod Data Presented at ASH 2021 Available on Active Biotech’s Website
Details : Preclinical data on drug tasquinimod, a small molecule immunomodulator Targets Immunosuppressive Myeloid Cells, Increases Osteogenesis and Has Direct Anti-Myeloma Effects by Inhibiting c-Myc Expression in Vitro and In Vivo.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
December 15, 2021
Lead Product(s) : Tasquinimod
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Laquinimod
Therapeutic Area : Ophthalmology
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
First Subject Dosed in Phase I Clinical Study with Eye-Drop Formulation of Laquinimod
Details : A preclinical program shows that the laquinimod eye-drop is safe and well tolerated, and the safety of this new formulation will now be tested in a phase I clinical study in healthy subjects.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
December 10, 2021
Lead Product(s) : Laquinimod
Therapeutic Area : Ophthalmology
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Naptumomab Estafenatox,Durvalumab
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : NeoTX Therapeutics
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Naptumomab estafenatox (NAP) is a cell therapy candidate, currently in Phase I. It is in clinical development for advanced solid tumors utilizing its proprietary Tumor Targeted Superantigen platform.
Product Name : Undisclosed
Product Type : Antibody-drug Conjugate
Upfront Cash : Inapplicable
November 30, 2021
Lead Product(s) : Naptumomab Estafenatox,Durvalumab
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : NeoTX Therapeutics
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tasquinimod,Ixazomib Citrate,Lenalidomide
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Tasquinimod is an oral immunomodulatory and anti-angiogenic investigational treatment, that affects the tumor’s ability to grow and metastasize. Tasquinimod is developed as a new immunomodulatory treatment for multiple myeloma.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
October 03, 2021
Lead Product(s) : Tasquinimod,Ixazomib Citrate,Lenalidomide
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Naptumomab Estafenatox,Durvalumab
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : NeoTX Therapeutics
Deal Size : Inapplicable
Deal Type : Inapplicable
Active Biotech Provides Status Update of its Clinical Naptumomab Project
Details : The study was amended to also include assessment of pre-treatment with obinutuzumab to assess its effect on anti-drug antibodies (ADAs) to naptumomab.
Product Name : Undisclosed
Product Type : Antibody-drug Conjugate
Upfront Cash : Inapplicable
July 05, 2021
Lead Product(s) : Naptumomab Estafenatox,Durvalumab
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : NeoTX Therapeutics
Deal Size : Inapplicable
Deal Type : Inapplicable